FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1924484409> ?p ?o ?g. }

• W1924484409 abstract "Background Peripheral arterial disease (PAD) affects 4% to 12% of people aged 55 to 70 years and 20% of people over 70 years. The most common complaint is intermittent claudication (IC) characterised by pain in the legs or buttocks that occurs with exercise and which subsides with rest. Compared with age‐matched controls, people with IC have a three‐ to six‐fold increase in cardiovascular mortality. Symptoms of IC, walking distance, and quality of life can be improved by risk factor modification, smoking cessation, and a structured exercise program. Antiplatelet treatment is beneficial in patients with IC for the reduction of vascular events but has not been shown to influence claudication distance. Objectives To determine the effect of cilostazol on improving walking distance and in reducing vascular mortality and cardiovascular events in patients with stable IC. Search methods The Cochrane Peripheral Vascular Diseases Group searched their specialised register (last searched August 2007) and the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3, 2007). We searched MEDLINE (1966 to November 2005), EMBASE (1980 to November 2005), several more specialised databases, and reference lists of articles. Selection criteria Double‐blind, randomised controlled trials of cilostazol versus placebo, or versus other antiplatelet agents in patients with stable IC or patients undergoing vascular surgical intervention for PAD. Data collection and analysis Two authors independently assessed trials for selection and all three authors independently extracted data. Main results Seven randomised controlled trials comparing cilostazol with placebo were included. The weighted mean difference (WMD) for the initial claudication distance (ICD) was improved following treatment with cilostazol 100 mg twice daily (WMD 31.1 m; 95% confidence interval (CI): 21.3 to 40.9 m) and 50 mg twice daily (WMD 41.3 m; 95% CI: ‐7.1 to 89.7 m) compared with placebo. Participants receiving cilostazol 150 mg twice daily had an increased ICD (WMD 15.7 m; 95% CI: ‐9.6 to 41.0 m) compared with those receiving placebo. One study also included a comparison with pentoxifylline. In this study, participants receiving cilostazol had significant improvement in ICD compared with placebo. There was no increase in major adverse events including cardiovascular events or mortality in patients receiving cilostazol compared with placebo. Authors' conclusions Patients with IC should receive secondary prevention for cardiovascular disease. Cilostazol has been shown to be of benefit in improving walking distance in people with IC. There are no data on whether it results in a reduction of adverse cardiovascular events." @default.
• W1924484409 created "2016-06-24" @default.
• W1924484409 creator A5000867068 @default.
• W1924484409 creator A5019475807 @default.
• W1924484409 creator A5029976609 @default.
• W1924484409 date "2008-01-23" @default.
• W1924484409 modified "2023-10-03" @default.
• W1924484409 title "Cilostazol for peripheral arterial disease" @default.
• W1924484409 cites W1486580743 @default.
• W1924484409 cites W1965470038 @default.
• W1924484409 cites W1973498254 @default.
• W1924484409 cites W1997451914 @default.
• W1924484409 cites W1998156657 @default.
• W1924484409 cites W2002893478 @default.
• W1924484409 cites W2024352468 @default.
• W1924484409 cites W2047644852 @default.
• W1924484409 cites W2057244473 @default.
• W1924484409 cites W2067784686 @default.
• W1924484409 cites W2070488805 @default.
• W1924484409 cites W2073412482 @default.
• W1924484409 cites W2087648579 @default.
• W1924484409 cites W2117838742 @default.
• W1924484409 cites W2125648462 @default.
• W1924484409 cites W2135562248 @default.
• W1924484409 cites W2144419036 @default.
• W1924484409 cites W2160629935 @default.
• W1924484409 cites W2164175810 @default.
• W1924484409 cites W4256353558 @default.
• W1924484409 cites W4256696377 @default.
• W1924484409 doi "https://doi.org/10.1002/14651858.cd003748.pub3" @default.
• W1924484409 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18254032" @default.
• W1924484409 hasPublicationYear "2008" @default.
• W1924484409 type Work @default.
• W1924484409 sameAs 1924484409 @default.
• W1924484409 citedByCount "88" @default.
• W1924484409 countsByYear W19244844092012 @default.
• W1924484409 countsByYear W19244844092013 @default.
• W1924484409 countsByYear W19244844092014 @default.
• W1924484409 countsByYear W19244844092015 @default.
• W1924484409 countsByYear W19244844092016 @default.
• W1924484409 countsByYear W19244844092017 @default.
• W1924484409 countsByYear W19244844092018 @default.
• W1924484409 countsByYear W19244844092019 @default.
• W1924484409 countsByYear W19244844092021 @default.
• W1924484409 countsByYear W19244844092022 @default.
• W1924484409 countsByYear W19244844092023 @default.
• W1924484409 crossrefType "reference-entry" @default.
• W1924484409 hasAuthorship W1924484409A5000867068 @default.
• W1924484409 hasAuthorship W1924484409A5019475807 @default.
• W1924484409 hasAuthorship W1924484409A5029976609 @default.
• W1924484409 hasConcept C126322002 @default.
• W1924484409 hasConcept C142724271 @default.
• W1924484409 hasConcept C168563851 @default.
• W1924484409 hasConcept C1862650 @default.
• W1924484409 hasConcept C204787440 @default.
• W1924484409 hasConcept C27081682 @default.
• W1924484409 hasConcept C2776478404 @default.
• W1924484409 hasConcept C2777466421 @default.
• W1924484409 hasConcept C2777628954 @default.
• W1924484409 hasConcept C2778963770 @default.
• W1924484409 hasConcept C2779820409 @default.
• W1924484409 hasConcept C2779881954 @default.
• W1924484409 hasConcept C3018348675 @default.
• W1924484409 hasConcept C535046627 @default.
• W1924484409 hasConcept C71924100 @default.
• W1924484409 hasConcept C95190672 @default.
• W1924484409 hasConceptScore W1924484409C126322002 @default.
• W1924484409 hasConceptScore W1924484409C142724271 @default.
• W1924484409 hasConceptScore W1924484409C168563851 @default.
• W1924484409 hasConceptScore W1924484409C1862650 @default.
• W1924484409 hasConceptScore W1924484409C204787440 @default.
• W1924484409 hasConceptScore W1924484409C27081682 @default.
• W1924484409 hasConceptScore W1924484409C2776478404 @default.
• W1924484409 hasConceptScore W1924484409C2777466421 @default.
• W1924484409 hasConceptScore W1924484409C2777628954 @default.
• W1924484409 hasConceptScore W1924484409C2778963770 @default.
• W1924484409 hasConceptScore W1924484409C2779820409 @default.
• W1924484409 hasConceptScore W1924484409C2779881954 @default.
• W1924484409 hasConceptScore W1924484409C3018348675 @default.
• W1924484409 hasConceptScore W1924484409C535046627 @default.
• W1924484409 hasConceptScore W1924484409C71924100 @default.
• W1924484409 hasConceptScore W1924484409C95190672 @default.
• W1924484409 hasLocation W19244844091 @default.
• W1924484409 hasLocation W19244844092 @default.
• W1924484409 hasOpenAccess W1924484409 @default.
• W1924484409 hasPrimaryLocation W19244844091 @default.
• W1924484409 hasRelatedWork W1978930988 @default.
• W1924484409 hasRelatedWork W1998156657 @default.
• W1924484409 hasRelatedWork W2011440291 @default.
• W1924484409 hasRelatedWork W2017654301 @default.
• W1924484409 hasRelatedWork W2025087614 @default.
• W1924484409 hasRelatedWork W2082521078 @default.
• W1924484409 hasRelatedWork W2146868637 @default.
• W1924484409 hasRelatedWork W2437908202 @default.
• W1924484409 hasRelatedWork W4312530846 @default.
• W1924484409 hasRelatedWork W4367473661 @default.
• W1924484409 isParatext "false" @default.
• W1924484409 isRetracted "false" @default.
• W1924484409 magId "1924484409" @default.
• W1924484409 workType "reference-entry" @default.